Infant Bacterial TherapeuticsB
Infant Bacterial Therapeutics AB is a Stockholm-based biopharmaceutical company focused on developing and commercializing medicines for diseases affecting premature infants. Its core program is IBP-9414, a live biotherapeutic product based on a human bacterial strain, alongside earlier-stage candidates for other neonatal and pediatric conditions.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueLate-stage neonatal therapy based on L. reuteri for preventing NEC in premature infants.
Earlier-stage programs including IBP-1016, IBP-1118 and IBP-1122.
Customers
IBT does not sell a broad commercial product portfolio today; its primary customers are expected to be hospitals, neonatal intensive care units, and healthcare systems that treat premature infants. In the development phase, the company also depends on regulators and clinical investigators, since approval and clinical evidence are prerequisites for eventual adoption by clinicians and payers.
Would use IBP-9414 to reduce NEC risk and related complications in premature infants.
Review clinical data and determine whether the product can be marketed.
Influence adoption by selecting therapies for high-risk preterm infants.
Would evaluate clinical value and reimbursement once commercialization starts.
Strategy
IBT’s strategy centers on advancing IBP-9414 through the regulatory pathway and preparing for potential commercialization in premature-infant care. The company also maintains a broader neonatal pipeline to extend its platform beyond the lead asset and address additional rare pediatric indications.
Marketing authorization is the key value-creation step for the lead asset.
A biologic for premature infants requires reliable contract manufacturing and quality control.
Additional programs reduce dependence on a single asset and extend the platform.
Geography
IBT is domiciled in Stockholm, Sweden and listed on Nasdaq Stockholm. Its business is globally oriented because the lead program is being developed for regulatory review in the United States and Europe, and the company’s cost base is exposed mainly to USD and EUR.
Risks
IBT is highly dependent on the success of IBP-9414 and on obtaining marketing authorization from the FDA and/or EMA. As a development-stage biotech, it also faces clinical, regulatory, manufacturing, and product-liability risks, while its cost base is sensitive to foreign-exchange movements in USD and EUR.
- Regulatory approval failure for IBP-9414Impact: CriticalLikelihood: Medium
The company’s value depends heavily on FDA/EMA authorization for the lead asset.
Exposure: Lead program and near-term valuation
- Clinical development riskImpact: HighLikelihood: Medium
Late-stage data may not translate into approval or commercial uptake.
Exposure: Phase III and follow-on studies
- Contract manufacturing dependenceImpact: HighLikelihood: Low
IBT relies on external manufacturers for commercial-scale supply and quality compliance.
Exposure: Future product launch and supply continuity
- Foreign exchange volatilityImpact: MediumLikelihood: Medium
Most development costs are incurred in foreign currencies, especially USD and EUR.
Exposure: Operating costs and cash position
- Product liability and insurance limitsImpact: MediumLikelihood: Low
Neonatal therapies and clinical trials can create claims if adverse events occur.
Exposure: Clinical and post-approval use
Accounting
Judgemental itemsOperating profit includes exchange-rate effects on currency investments intended to secure future payments.
Impact: Can materially move reported operating loss quarter to quarter
Development-stage biotech costs are generally expensed as incurred.
Impact: Drives reported losses before commercialization
The company does not apply IFRS 16 in its legal-entity reporting and expenses leases straight-line.
Impact: Affects balance sheet leverage and EBITDA comparability
Net sales are zero in the reported period, so there is no product revenue timing issue yet.
Impact: Commercial launch will introduce revenue recognition judgment
Similar listed companies
Publicly listed companies with a comparable business focus.
Healthier Choices Management Corp.
HCMC · Tobacco Products
Hong Yuan Holding Group
HGYN · Plastic Materials, Synth Resins & Nonvulcan Elastomers
HONG YUAN HOLDING GROUP is a U.S.-listed company in the plastics and synthetic resins value chain.
Valuence Merger Corp. I
VMCUF · Blank Checks
Valuence Merger Corp.
American Exceptionalism Acquisition Corp. A
AEXA · Blank Checks
American Exceptionalism Acquisition Corp.
Artificial Intelligence Technology Solutions Inc.
AITX · Services-Prepackaged Software
Amgen Inc
AMGN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026